Akopyan Kristina, Shah Aman, Rackauskas Mindaugas, Gries Cynthia, Emtiazjoo Amir, Saha Biplab K
Internal Medicine, University of Florida, Gainesville, USA.
Cardiology, University of Florida, Gainesville, USA.
Cureus. 2024 Jun 18;16(6):e62638. doi: 10.7759/cureus.62638. eCollection 2024 Jun.
Persistent sinus tachycardia (pST) has been associated with adverse cardiovascular events in critically ill patients. Pharmacological control of heart rate with negative inotropic agents has proven to be safe but could be potentially dangerous in patients with concomitant right ventricular (RV) dysfunction. Ivabradine, a medication devoid of negative inotropy, could be a potentially safe solution for this patient population when adequate heart rate control is desired. A 17-year-old male with a history of vaping developed acute respiratory distress syndrome (ARDS) and RV dysfunction, requiring extra corporal life support (ECLS). He suffered from pST. Given his RV dysfunction, a beta-blocker was avoided, and ivabradine was used safely with improvement of his pST. This case demonstrates the efficacy of ivabradine to reduce heart rate and avoid the use of beta-blockers for patients with RV dysfunction, which could be detrimental. Ivabradine was shown to lower the heart rate without altering hemodynamic parameters.
持续性窦性心动过速(pST)与危重症患者的不良心血管事件相关。使用负性肌力药物进行心率的药物控制已被证明是安全的,但对于伴有右心室(RV)功能障碍的患者可能存在潜在危险。伊伐布雷定是一种无负性肌力作用的药物,在需要充分控制心率时,对于这类患者群体可能是一种潜在安全的解决方案。一名有电子烟吸食史的17岁男性发生急性呼吸窘迫综合征(ARDS)和RV功能障碍,需要体外生命支持(ECLS)。他患有pST。鉴于其RV功能障碍,避免使用β受体阻滞剂,伊伐布雷定被安全使用,其pST得到改善。该病例证明了伊伐布雷定降低心率以及避免对RV功能障碍患者使用β受体阻滞剂的有效性,而使用β受体阻滞剂可能是有害的。结果显示伊伐布雷定可降低心率而不改变血流动力学参数。